KLRS vs KROS Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — KROS scores higher on quality with 8.6/10 vs KLRS's 4.1/10. KLRS trades at $4.65 while KROS trades at $10.55. Both analyzed daily using SEC EDGAR data across 13 institutional models.

KLRS

Biotechnology

Kalaris Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

30

LOW

Price

$4.65

Last close

Models

7/13

Active

VS

KROS

Biotechnology

Keros Therapeutics, Inc.

Quality

8.6

out of 10

Value Trap

6

SAFE

Price

$10.55

Last close

Models

8/13

Active

KLRS

2 models active

Quality 4.1/10 — below average

KROS

Earnings Power Value sees +278.0% upside

Limited to 2/13 visible models

KLRS vs KROS — Fair Value Comparison

KLRS

KROS

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	KLRS Fair Value	KLRS Upside	KROS Fair Value	KROS Upside
Bayesian DCF	Intrinsic	$0.36	-92.2%	—	—
Earnings Power Value	Intrinsic	—	—	$39.88	+278.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.17	-74.7%	$20.22	+91.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

KLRS vs KROS — Which Stock Is More Undervalued in 2026?

KROS scores higher with a 8.6/10 quality rating vs KLRS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do KLRS and KROS Valuations Compare?

KLRS currently trades at $4.65 while KROS trades at $10.55. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily for both companies.

Quality of Company: KLRS vs KROS

KLRS earns a Quality of Company score of 4.1/10 compared to KROS's 8.6/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: KLRS vs KROS

KLRS carries a LOW value trap risk (30/100) while KROS shows SAFE risk (6/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Biotechnology

Both KLRS and KROS operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare KLRS vs KROS differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

KLRS

View Full Kalaris Therapeutics, Inc. Analysis →

KROS

View Full Keros Therapeutics, Inc. Analysis →

See all Biotechnology stocks →